Neurosoft closed a $7.5M oversubscribed seed round led by Skybound Venture Capital, bringing total funding past $20M. The proceeds will advance the company's soft, stretchable cortical electrode platform, claimed to be up to 1,000x more compliant than other flexible interfaces, and fund early development of a cortical foundation model. Participation by Protocol Labs puts Neurosoft in the same investment portfolio as US BCI leaders including Synchron and Science Corp.